Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations, claiming that the move ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

Johnson & Johnson's hopes of quickly building its new cancer drug Rybrevant into a $5 billion product have been undermined by an FDA decision. The US regulator has turned down J&J's marketing ...

At its third attempt, Mesoblast has secured FDA approval for Ryoncil as a treatment for children with graft-versus-host disease, the first-ever approval for a mesenchymal stromal cell (MSC ...

As large-molecule drugs and weight-loss therapeutics dominate headlines, the pharmaceutical industry faces legislative pressures, funding cuts, and cascading supply chain disruptions. This ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for autoimmune diseases, with chimeric antigen receptor (CAR)-T therapies ...

It was the day we’d all been waiting for. Rachel Reeves’ Autumn Budget felt like it had been on the horizon for a while. And it was great to see a commitment to the NHS, with an extra £22.6 ...

Prominent podcaster Steven Bartlett has been accused of allowing misleading health information to be shared on his Diary of a CEO stream, which has millions of subscribers. A BBC investigation ...